Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant human monoclonal antibody expressed in CHO binding to toxin A [C. difficile]. Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficileinfection.
Target
toxin A [C. difficile]
Type
IgG1 - kappa
Immunogen
The details of the immunogen for this antibody are not available.
Species Reactivity
C. difficile
Expression Host
CHO
Applications
Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, WB and most other immunological methods.
CAS
1245634-25-6
Predicted N terminal
QVQLVESG
Molecular Weight
145.9 kDa
Purity
>95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
Size
1mg
Storage
Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.
BACKGROUND
Introduction
Clostridium difficile, or C. difficile, a gram positive anaerobic bacterium, is the major causative agent of colitis and diarrhoea that can occur following antibiotic intake. C. difficile infection is one of the most common hospital acquired infections. When C. difficile colonize the gut, they release two potent toxins, toxin A and toxin B, which bind to certain receptors in the lining of the colon and ultimately cause diarrhoea and inflammation of the large intestine.
Antigen Description
Clostridium difficile, or C. difficile, a gram positive anaerobic bacterium, is the major causative agent of colitis and diarrhoea that can occur following antibiotic intake. C. difficile infection is one of the most common hospital acquired infections. When C. difficile colonize the gut, they release two potent toxins, toxin A and toxin B, which bind to certain receptors in the lining of the colon and ultimately cause diarrhoea and inflammation of the large intestine.